Few topics in healthcare have generated as much buzz — and as much disruption — as GLP-1 medications. Originally developed to treat type 2 diabetes, drugs like Ozempic, Wegovy, and Mounjaro are now widely prescribed for weight management. Their effectiveness has made them headline news, but it’s their price tag and rapid adoption that are rewriting the rules for health insurance.
The Demand
According to KFF, about one in eight U.S. adults has used a GLP-1 medication at some point. These drugs are remarkably effective: clinical studies show average weight loss of 10–15 percent and improved cardiovascular and metabolic outcomes. With obesity affecting over 40 percent of adults nationwide (CDC, 2024), the potential market is massive.
The Cost
That promise carries a price. The Employee Benefit Research Institute (EBRI) found that the net monthly cost of GLP-1 drugs ranges from $617 to $766, or more than $12,000 per year per patient. When EBRI modeled what widespread coverage would mean for employer health plans, the results were striking:
- With current drug prices and typical real-world adherence, premiums rose 6.1% when coverage was limited to people with both diabetes and obesity — and 10.4% when it expanded to include overweight individuals.
- If every patient adhered perfectly to treatment, premiums increased 8.1% to 13.8%, even after adding cost-sharing measures like a $90 copay, which reduced costs only modestly.
- When researchers modeled a lower-cost GLP-1 ($200 per month), the impact fell dramatically — to 1–3.9%, depending on adherence and eligibility
The Coverage
Pharmacy benefits weren’t built for this kind of change. Formularies were never designed for high-cost, long-term medications prescribed at this scale. As adoption grows, employers and insurers are asking critical questions:
- Should GLP-1s be covered for weight management or only for diabetes?
- How do plans balance affordability with access for those who need them most?
- Can broader coverage eventually reduce obesity-related healthcare costs?
The Future
GLP-1s highlight a larger truth: innovation in medicine doesn’t just reshape clinical care — it reshapes insurance. These drugs force stakeholders to rethink how benefits are structured, how cost is shared, and how long-term value is measured.